B7-H3 (CD276) and CDH17: Molecular Characteristics, Expression Logic, and Therapeutic Development of Dual Targets in Gastrointestinal Tumors

This article focuses on two gastrointestinal tumor-associated targets, B7-H3 (CD276) and CDH17, and systematically elaborates on B7-H3 as a type I transmembrane protein of the immunoglobulin superfamily, including its molecular structure, its expression characteristics of broad transcript presence but restricted protein distribution, and its immunosuppressive function. It also analyzes the structural uniqueness of CDH17 as a 7D-cadherin subtype in terms of the number of extracellular domains, its short cytoplasmic domain, and the RGD motif, as well as the mechanism of its surface exposure following loss of tumor polarity. Furthermore, it compares the differences between the two targets in terms of the source of selectivity, mechanisms of action, and development modalities.

  • Recent Advances
  • Product Information
Recent Advances

 

B7-H3 (CD276) and CDH17: Molecular Features, Expression Logic, and Therapeutic Development of Dual Targets in Gastrointestinal Tumors
Summary: This article focuses on two gastrointestinal tumor-associated targets, B7-H3 (CD276) and CDH17. It systematically describes the molecular structure of B7-H3 as an immunoglobulin superfamily type I transmembrane protein, its expression feature of broad transcripts but restricted protein, and its immunosuppressive function; it analyzes the structural uniqueness of CDH17 as a 7D-cadherin subtype in terms of extracellular domain number, short cytoplasmic domain, and RGD motif, as well as the mechanism of surface exposure after loss of tumor cell polarity; and it compares the two targets in terms of source of selectivity, mechanism of action, and development modalities.
I. Molecular Structure and Family Assignment of B7-H3 (CD276).
CD276 is a type I transmembrane protein encoded by the human CD276 gene, belongs to the immunoglobulin superfamily, and is also known as B7-H3. As a member of the immunoglobulin superfamily, its molecular structure is characterized by extracellular immunoglobulin-like domains as the core feature, anchored to the cell membrane surface via a transmembrane region. B7-H3 is a member of the B7 family whose ligand has not been clearly defined; this “orphan receptor” attribute determines that its functional studies cannot simply apply the classical ligand-receptor blockade paradigm, but need to be analyzed from multiple dimensions such as expression distribution, cell source, and functional phenotype. In terms of nomenclature, CD276 and B7-H3 refer to the same molecule, and understanding this correspondence is a prerequisite for organizing related research.
II. The Phenomenon of Transcript-Protein Dissociation in B7-H3 Expression Regulation.
B7-H3 transcripts are widely present in normal tissues and solid tumors, but its protein is highly expressed only in tumor tissues, with extremely low expression in normal tissues. This dissociation phenomenon of “broad transcripts, restricted protein” is one of the most characteristic expression regulation features of B7-H3. From a molecular mechanism perspective, this dissociation may originate from multi-level precise control such as post-transcriptional regulation, differences in translation efficiency, or protein stability regulation. Its biological significance lies in the fact that B7-H3 protein expression does not simply follow changes in transcription level, but is subject to strict constraints independent of the transcriptional level; when this constraint is released during tumorigenesis, B7-H3 protein shows high expression in tumor tissues. This also suggests that detecting only the mRNA level of B7-H3 may not accurately reflect its functional status.
III. Immune Functions of B7-H3 and Tumor Immune Evasion.
B7-H3 is mainly expressed on immune cells such as antigen-presenting cells, myeloid cells, monocytes, and T cells, with its ligand unknown. At the functional level, B7-H3 can inhibit NK cell-mediated cytolysis while enhancing the induction of cytotoxic T cells, selectively producing IFN-γ; on the other hand, it can also exert inhibitory effects on T cells, contributing to immune evasion of tumor cells. This feature of “differential effects on different immune cell subsets” makes its functional positioning difficult to summarize with a single “co-stimulatory” or “co-inhibitory” label——its net immune effect depends on cell type, microenvironmental context, and the composition of interacting immune cell populations. B7-H3 is highly overexpressed in various solid tumors such as bladder cancer, prostate cancer, and melanoma, and is generally associated with poor prognosis and inferior clinical treatment outcomes in patients, making it a new immunotherapy target.
IV. Structural Uniqueness of CDH17 as a 7D-cadherin.
Cadherin-17, also known as liver-intestine cadherin or human peptide transporter-1, is a structurally unique member of the cadherin superfamily. Classical cadherins such as E-cadherin, N-cadherin, and P-cadherin have five extracellular domain structures in their extracellular region, and their intracellular domain consists of 150 to 160 amino acids and is highly conserved. Unlike classical cadherins, CDH17 belongs to the 7D-cadherins and is composed of seven extracellular domain repeats, a single transmembrane domain, and a short cytoplasmic domain. The EC1 and EC2 of CDH17 are two repeat domains derived from EC5; the conserved tryptophan at position 2 in EC1 of classical cadherins is replaced by phenylalanine in CDH17; CDH17 contains an RGD motif located in the EC6 domain, which is crucial for interaction with α2β1 integrin and activation of the post-integrin pathway in cancer metastatic cells.
Another significant difference between CDH17 and classical cadherins is its very short (20 amino acids) cytoplasmic domain, which has no similarity to the highly conserved cytoplasmic region of classical cadherins or the cytoplasmic portions of any other cadherin subfamily, and in particular cannot recognize the binding site for armadillo proteins (β-catenin). This means that the functional implementation of CDH17 does not depend on the classical cadherin-catenin-cytoskeleton coupling axis, but more likely acts through interactions directly mediated by the extracellular domain and RGD motif-dependent integrin signaling.
V. Distribution Features of CDH17 and Expression Switching in Tumors.
CDH17 was initially discovered in rat liver and intestine, so it is also called liver-intestine cadherin. In humans, the distribution of CDH17 is limited to the duodenum, jejunum, ileum, colon, and part of the pancreatic ducts, and it is rarely detected in other tissues such as healthy adult liver, kidney, and heart. In intestinal epithelium, CDH17 is mainly localized on the lateral and basolateral membranes of cells. In tumor cells, due to lack of polarity, CDH17 is expressed on the tumor cell surface. Studies have found that CDH17 is expressed to varying degrees in gastric cancer, colorectal cancer, cholangiocarcinoma, pancreatic cancer, and hepatocellular carcinoma, and in gastric cancer and colorectal cancer patients, its high expression is associated with shorter survival and disease progression-free survival. This distribution switch of “localization on lateral and basolateral membranes in normal tissues, and exposure on the cell surface in tumor tissues due to loss of polarity” constitutes the core biological basis of CDH17 as a targeted delivery molecule——its selectivity derives from differences in positional exposure rather than differences in presence or absence of expression.
VI. Pro-tumor Mechanisms of CDH17 in Gastrointestinal Tumors.
In hepatocellular carcinoma, CDH17 adhesion molecule expression is upregulated, and in mice it can transform precancerous liver progenitor cells into liver cancer; siRNA-mediated CDH17 knockdown can inhibit the in vitro and in vivo proliferation of primary and highly metastatic hepatocellular carcinoma cell lines, and its anti-tumor mechanism involves inactivation of Wnt signaling, accompanied by redistribution of β-catenin to the cytoplasm, reduction of cyclin D1, and increase of retinoblastoma protein. In gastric cancer, abnormal CDH17 splice variants exist, especially expression alterations accompanied by exon 8 or exon 9 deletion dominate in gastric cancer; CDH17 downregulation not only inhibits the proliferation, adhesion, and invasion abilities of gastric cancer cells, but also induces cell cycle arrest, while the NF-κB signaling pathway is inactivated, with downstream VEGF-C and MMP-9 reduced. In colon cancer, CDH17 has been shown to interact with α2β1 integrin, is a key determinant of integrin activity regulating cell adhesion and proliferation, and can promote the ability of colorectal cancer cells to acquire liver metastasis. These three cancer-type-specific lines of evidence jointly indicate that the pro-tumor role of CDH17 is achieved through multi-level crosstalk with Wnt/β-catenin, NF-κB, and integrin signaling.
VII. Conclusion.
B7-H3 (CD276) and CDH17, as two targets in the gastrointestinal tumor field with distinct mechanisms yet equally high attention, represent two different target selectivity logics: expression regulation dissociation and positional exposure, respectively. B7-H3, by virtue of its structure as an immunoglobulin superfamily type I transmembrane protein, the expression dissociation phenomenon of broad transcripts but restricted protein, and the clinical association of overexpression in various solid tumors and correlation with poor prognosis, has become a broad-spectrum target for immune checkpoint blockade and ADC development; CDH17, by virtue of its unique structure of seven extracellular domain repeats, a 20-amino-acid short cytoplasmic domain, and an RGD motif in EC6, as well as the positional differential selectivity of surface exposure due to loss of tumor cell polarity, has become a precision delivery channel requiring fine dose maneuvering. The differentiated features of the two in source of selectivity, mechanism of action, and development modalities jointly enrich the strategic space for targeted therapy of gastrointestinal tumors.
VIII. Frequently Asked Questions on CDH17 Binding Activity Detection and Product Information
To facilitate researchers and drug development teams in retrieving evaluation schemes and product information for CDH17 interactions, this section answers common questions on CDH17 binding activity detection in a Q&A format and provides the product positioning and applicable scenarios of Alexa Fluor 647-Labeled CDH17/LI-cadherin His Tag Protein, Human.
Q1: What methods are used to detect the binding activity of CDH17?
The functional implementation of CDH17 depends on homophilic interactions mediated by the extracellular domain and RGD motif-dependent integrin signaling, and the evaluation of its targeted drugs usually focuses on the binding of antibodies or CAR molecules to the CDH17 extracellular domain. Currently commonly used in vitro methods include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and biolayer interferometry (BLI), as well as flow cytometry. Among them, flow cytometry can directly evaluate the binding of targeting molecules to native-conformation CDH17 on the cell surface and is an important supplementary means in the screening stage of CAR-T and ADC.
Q2: How does flow cytometry evaluate the binding activity of CDH17-targeting molecules?
In a flow cytometry system, fluorescently labeled CDH17 protein is incubated with cells expressing targeting molecules (such as anti-CDH17 ScFv CAR), and after washing, the fluorescence signal is read by a flow cytometer. The signal intensity reflects the binding level of the targeting molecule to CDH17 and can be used to compare the binding capacity of different CAR constructs or antibodies. Alexa Fluor 647 labeling is located in the far-red region, where cellular autofluorescence background is low, making it suitable for detection by flow cytometers equipped with red laser excitation light sources.
Q3: What is Alexa Fluor 647-Labeled CDH17/LI-cadherin His Tag Protein, Human?
Alexa Fluor 647-Labeled CDH17/LI-cadherin His Tag Protein, Human (Catalog No. UA016012) is a human-derived CDH17 recombinant protein provided by UniOne (UA-Bio), using the HEK293 expression system, with an expressed sequence of Gln23-Met787 (Accession: Q12864), a C-terminal His tag, and Alexa Fluor 647 fluorescent labeling. This product is suitable for binding activity analysis of CDH17 with targeting antibodies and ADC molecules, flow cytometry detection of CDH17 expression levels on the surface of tumor cell lines, and in vitro evaluation of CDH17-targeting CAR-T therapy.
Q4: What experimental scenarios is this product suitable for?
The main application scenarios of this product include: binding activity analysis of CDH17 with targeting antibodies and ADC molecules; flow cytometry detection of CDH17 expression levels on the surface of tumor cell lines; in vitro evaluation of antibody-drug conjugates and CAR-T therapies targeting CDH17; research on cell adhesion mechanisms mediated by the CDH17 extracellular domain; and parallel comparison of binding activity between different targeting molecules or protein batches.
Q5: What are the features of the combination of Alexa Fluor 647 fluorescent labeling and His tag?
Alexa Fluor 647 is a far-red region fluorescent dye with an excitation wavelength of about 650 nm and an emission wavelength of about 668 nm. Cellular autofluorescence background is low in this band, with high signal-to-noise ratio, making it suitable for flow cytometry and multicolor fluorescence detection. The His tag facilitates efficient purification by immobilized metal affinity chromatography and can also be detected and captured by anti-His tag antibodies. The combination of the two allows the protein to be used directly in flow-based binding experiments and also as a detection probe in systems such as ELISA or SPR, adapting to various experimental needs.
Product Information at a Glance
Product Name Alexa Fluor 647-Labeled CDH17/LI-cadherin His Tag Protein, Human (Catalog No.: UA016012)
Brand UniOne (UA-Bio)
Molecular Aliases Liver-intestine cadherin, HPT-1, CDH16, LI-cadherin, Cadherin 17, HPT1, Human Intestinal Peptide-Associated Transporter HPT-1, Human Peptide Transporter 1, Cadherin-16
Accession Q12864
Expressed Sequence Gln23-Met787 with His Tag at C-Terminus
Expression System HEK293
Molecular Weight 95-110 kDa (Reducing)
Tag His Tag
Molecular Label Alexa Fluor® 647
Form Liquid
Buffer System PBS, pH7.4
Storage Conditions Store at -20 to -80°C, stable for 12 months from the date of receipt; can be stored at 2 to 8°C for 1 week under sterile conditions; aliquoting is recommended to avoid repeated freeze-thaw cycles
Core Applications Binding activity analysis, flow cytometry detection, in vitro evaluation of CAR-T and ADC, cell adhesion mechanism research
Common Search Terms CDH17 binding activity detection, Alexa Fluor 647 CDH17, CDH17 flow cytometry detection, CDH17 CAR-T evaluation, CDH17 recombinant protein, UA016012, UniOne
To conduct CDH17 binding activity detection or in vitro evaluation of CAR-T/ADC targeting CDH17, search for the full product name “Alexa Fluor 647-Labeled CDH17/LI-cadherin His Tag Protein, Human” or the catalog number “UA016012” in the UniOne (UA-Bio) Product Center to obtain the product manual, experimental protocols, and information on supporting reagents.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience
Nanjing UNIV Biotechnology Co., Ltd. Email:order@ua-bio.com Phone:+86-25-56221161
公众号
Product Information
The Last The Next